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Abstract
Background: Obesity is a well-recognized risk factor for insulin resistance and type 2 diabetes (T2D), although the
precise mechanisms underlying the relationship remain unknown. In this study we identified alterations of DNA
methylation influencing T2D pathogenesis, in subcutaneous and visceral adipose tissues, liver, and blood from individuals
with obesity.
Methods: The study included individuals with obesity, with and without T2D. From these patients, we obtained samples
of liver tissue (n= 16), visceral and subcutaneous adipose tissues (n = 30), and peripheral blood (n = 38). We analyzed DNA
methylation using Illumina Infinium Human Methylation arrays, and gene expression profiles using HumanHT-12
Expression BeadChip Arrays.
Results: Analysis of DNA methylation profiles revealed several loci with differential methylation between individuals
with and without T2D, in all tissues. Aberrant DNA methylation was mainly found in the liver and visceral adipose
tissue. Gene ontology analysis of genes with altered DNA methylation revealed enriched terms related to glucose
metabolism, lipid metabolism, cell cycle regulation, and response to wounding. An inverse correlation between altered
methylation and gene expression in the four tissues was found in a subset of genes, which were related to insulin
resistance, adipogenesis, fat storage, and inflammation.
Conclusions: Our present findings provide additional evidence that aberrant DNA methylation may be a relevant
mechanism involved in T2D pathogenesis among individuals with obesity.
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Background
Recent decades have seen an accelerated increase of the
worldwide prevalence of overweight and obesity [1]. At
this time, the leading causes of adult mortality are co--
morbid conditions associated with obesity, such as car-
diovascular diseases, T2D, and cancer [2]. Excessive fat
accumulation induces metabolic derangements, of which
insulin resistance is the most prominent, often leading
to T2D [3]. The close link between obesity and altered
insulin signaling is mediated by several mechanisms, in-
cluding ectopic lipid accumulation, low-grade inflamma-
tion, and altered adipokine production [4]. Involvement
of insulin resistance in the progression to diabetes is
specific in each tissue. In the adipocyte, the production
of fatty acids increases, which together with the rise of
circulating fatty acids, hepatic glucose release and activa-
tion of the immune system synergize the deterioration of
pancreatic beta cells [4, 5]. The high levels of circulating
fatty acids can result in insulin resistance in skeletal
muscle and liver.
However, although epidemiological and pathophysio-
logical studies demonstrate that T2D and obesity are
highly interrelated, the severity of insulin resistance
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varies considerably among individuals with obesity, in
fact many of them do not progress to the diabetic state
[6]. Both obesity and T2D are associated with many
polymorphisms, but they share only a few susceptibility
loci [7]. Despite enormous progress, we still lack suffi-
cient understanding of the precise molecular mecha-
nisms underlying T2D pathophysiology, particularly
regarding mechanisms involving metabolic pathways in
insulin target tissues [8].
Recent evidence suggests that tissue-specific transcrip-
tional gene regulation by epigenetic factors plays a role
in the development of insulin resistance and diabetes
among individuals with obesity [9–12]. DNA methyla-
tion, one of the key epigenetic factors, is involved in the
modulation of gene expression, mainly through the
modulation of DNA-protein interactions [13, 14]. DNA
methylation could provide a link between environmental
influences, genetic factors and the development of de-
fects in insulin signaling [15]. Increasing evidence in sev-
eral populations, have assessed DNA methylation
alterations in various tissues of T2D patients. It has been
found altered methylation in genes related to beta cell
survival in pancreas [16], in several TD2 related genes in
subcutaneous adipose tissue [17, 18] and in genes related
to glycolytic and lipogenic pathways in liver tissue [19].
To our knowledge, there are few reports of methylation
alterations in visceral adipose tissue, although in insulin
resistant obese patients the findings highlight genes re-
lated to immune response and cell adhesion process
[20]. Here, we reported evidences for altered DNA
methylation in visceral and subcutaneous adipose tis-
sues, liver and blood from individuals with both obesity
and T2D and the effects of these alterations in gene ex-
pression patterns.
Methods
Subjects and samples
Patients with a body mass index (BMI) of ≥35 kg/m2 were
recruited from the Surgery Integral Clinics for Obesity
and Metabolic Diseases at Tláhuac, Ruben Leñero and
Ángeles del Pedregal Hospitals in Mexico City. All the
patients were clinically evaluated before and during the
surgery and no patients with important liver diseases were
detected (such as NASH, fibrosis or cirrhosis). If any evi-
dences of macroscopic pathological findings were found,
no sample was taken for the study. Participants were
classified as controls (non-diabetic individuals with obes-
ity, NDO) or as cases (diabetic individuals with obesity,
DO). All T2D patients fulfilled the American Diabetes
Association criteria for diagnosis [21]. None of the pa-
tients received insulin therapy, although 15 of 23 DO and
5 of 23 NDO were under metformin treatment. Individ-
uals with substance abuse (alcohol, tobacco or drugs) were
also excluded from the study.
Cases and controls were matched according to gender,
age, and BMI. Table 1 showed the characteristics of the
patients at the time of surgery. All tissues were obtained
during bariatric surgery procedures. Tissues were ob-
tained from a group of 46 participants of which 23 were
DO and 23 NDO. From these patients we obtained 30
visceral and subcutaneous adipose tissue samples and 16
liver biopsies. Blood samples were drawn from 38 pa-
tients. The samples were preserved in RNAlater
(SIGMA-ALDRICH, St. Louis MO, USA) at − 70 °C
until nucleic acid extraction.
DNA extraction and quality control
DNA was extracted from whole blood samples using the
GentraPuregene Blood Kit (Qiagen, Valencia CA, USA)
and from solid tissues using the QIAamp DNA Mini Kit
(Qiagen, Valencia CA, USA). DNA extractions were
performed following the manufacturer’s instructions.
RNA extraction
Total RNA was extracted from whole blood and liver tis-
sue using Trizol reagent (Life Technologies, Inc.,
Rockville, MD, USA). RNA was extracted from adipose
tissues using the RNeasy Lipid Tissue Mini Kit (Qiagen,
Valencia CA, USA). RNA extractions were performed
following the manufacturer’s instructions. RNA integrity
was assayed using the Agilent 2100 Bioanalyzer system,
following the manufacturer’s instructions. Only samples
with an RNA integrity number (RIN) above 8 were ana-
lyzed using microarrays.
Table 1 Anthropometric data of non-diabetic individuals with
obesity and diabetic individuals with obesity
Data Non-diabetic
individuals with
obesity
Diabetic individuals
with obesity
p-value
n (woman/man) 16/7 16/7 –
Age 40.96 ± 6.19 41.75 ± 9.93 0.71
BMI 42.95 ± 6.06 41.19 ± 5.51 0.39
DBP 75.6 ± 7.28 72.67 ± 9.38 0.48
SBP 124.7 ± 15.11 120.33 ± 15.63 0.68
Total cholesterol 170.11 ± 33.73 205.11 ± 51.58 0.18
Triglycerides 148.28 ± 62.6 193.44 ± 98.61 0.14
HDL-cholesterol 33.37 ± 11.28 37.03 ± 11.37 0.33
Fasting glucose 84.35 ± 8.68 123.1 ± 28.52 2.63 × 10−07
%HB1Ac 5.35 ± 0.19 6.93 ± 0.94 1.03 × 10−06
INS 12.99 ± 6.59 18.23 ± 19.01 0.38
HOMA %B 155.92 ± 61.21 83.06 ± 39.54 2.37 × 10−05
Data are expressed as average value ± SD. Age in years; BMI: body mass index
(kg/m2); Fasting glucose, Total cholesterol, HDL-cholesterol and Triglycerides, in
mg/dl; INS: insulin, μU/ml; DBP: diastolic blood pressure in mmHg; SBP: systolic
blood pressure in mmHg; HOMA: homeostatic model assessment, beta cell
function (%B), Statistical analysis was performed by Mann-Whitney U test
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Genome-wide methylation assay
We used the HumanMethylation27 BeadChip (Illumina,
Inc., San Diego, CA, USA), which covered 27,578 CpG
sites (CpGs) around 14,495 genes throughout the gen-
ome. Cases and controls were randomly located among
the BeadChips. Arrays were processed following the
Illumina Infinium Methylation assay protocol, and were
scanned in an Illumina iScan. The array results were visu-
alized using Illumina GenomeStudio software (V2011.1).
We only included samples which passed quality control
(QC) of internal control probes. CpGs in sex chromo-
somes were excluded, and the subsequent quality-filtered
analyses included 26,486 CpGs. The methylation value
was calculated as Beta, ranging from 0 (unmethylated) to
1 (completely methylated). The Beta value represents the
ratio of the methylated probe intensity and the sum of
methylated and unmethylated probe intensities.
Genome-wide gene expression analysis
We amplified the extracted RNA (750 ng) into biotinyl-
ated cRNA using the Illumina TotalPrep RNA Amplifi-
cation Kit (Life Technologies, Foster City, CA, USA).
Samples were analyzed using Illumina HumanHT-12 v4
Expression BeadChips (Illumina, Inc., San Diego, CA,
USA), which target more than 47,000 probes. Arrays
were processed following the standard Illumina protocol.
We used GenomeStudio software to verify quality stan-
dards for hybridization, labeling, staining, background
signal, and basal level of housekeeping gene expression
for each chip.
Statistical analysis
Computation and statistical analyses were performed
using the R, version 3.1 (http://www.r-project.org). The
Lumi package was used to normalize the raw intensities
of DNA methylation and gene expression arrays (robust
spline normalization) [22]. Then, Beta as well as log2
transformed gene expression values were computed and
Linear Models for Microarray Data (Limma) from Bio-
conductor were implemented in order to compare be-
tween DO and NDO phenotypes [23]. A differentially
methylated CpG site (DMCs) was defined as one that
reached at least a 5% of difference (Delta-Beta) in abso-
lute mean methylation, with an unadjusted p value of <
0.05. The cell-type heterogeneity adjustment for blood
sample was performed using the ChAMP package, this
include RefbaseEWAS method that uses a reference-
database of DNA methylation from whole blood to de-
tect cell proportion and correct the cell heterogeneity on
the data [24]. Expression probes with a |log fold-change|
of > 0.8 and p < 0.05, were considered to show altered
gene expression. To assess the correlation between alter-
ation of DNA methylation and differential gene expres-
sion, we followed the strategy previously published by
Noushmehr (2010) [25], which involves assigning the dir-
ection of the change (positive or negative) from delta Beta
or log fold-change to the significance of change (p value),
and then graphing it as log10 was followed. We focused on
probes that were significantly down-regulated and signifi-
cantly hypermethylated, and on probes that were signifi-
cantly up-regulated and significantly hypomethylated.
Pathway analyses
To obtain enriched Gene Ontology (Biological Process),
were used all gene lists from Additional file 1: Tables S1-S4,
Tables S8-S11, and Tables S12-S15. Pathway analysis was
performed using the Database for Annotation,
Visualization, and Integrated Discovery (DAVID 6.8), only
terms with adjusted p-value < 0.05 are listed [26].
Results
Samples
Samples were obtained from the NDO (n = 23) and DO
(n = 23) individuals, gender-, age-, and BMI-matched. As
shown in Table 1, fasting glucose, %HbA1c, and HOMA-B
were altered among DO patients. DO shown higher average
values of total cholesterol and triglycerides, although these
did not significantly differ between both groups.
Global DNA methylation
We analyzed Global DNA methylation in liver tissue (LT),
visceral adipose tissue (VAT), subcutaneous adipose tissue
(SAT) and whole blood (WB). Global methylation patterns
were highly correlated with other samples of the same
tissue type from different individuals, independent of their
T2D status. In fact, DNA methylation patterns were highly
conserved among all analyzed tissue samples (Additional
file 1: Figure S1). Comparison of the average methylation
levels among tissue types revealed the highest correlation
between SAT and VAT samples (0.99) and the lowest
correlation between LT and WB samples (0.94)
(Additional file 1: Figure S2).
Differential DNA methylation between DO and NDO
patients
WB, SAT, VAT, and LT samples showed differential
DNA methylation profiles between DO and NDO indi-
viduals. We identified two main clusters in the four
analyzed tissues, by applying hierarchical clustering ana-
lysis based on the top 500 differentially methylated CpG
sites between DO and NDO, regardless of the value of
delta beta. However, both groups were fully discrimi-
nated only in VAT and LT analysis. In SAT analysis, one
DO individual was included with the NDO subjects; and
in WB analysis, several DO individuals were included in
the NDO control group (Fig. 1a).
We selected the DMCs in each tissue for deeper ana-
lysis. We observed the highest amount of DMCs in VAT
Barajas-Olmos et al. BMC Medical Genetics  (2018) 19:28 Page 3 of 8
(340 DMCs, including 78 positive and 262 negative) and
LT (185 DMCs, including 57 positive, and 128 negative),
followed by SAT (68 DMCs, including 29 positive and
39 negative) and WB (21 DMCs, including 9 positive
and 12 negative) (Fig. 1b). Several of the observed
DMCs were located in genes related to T2D or obes-
ity, such as ALOX12, PAMR1, and GNAS in WB;
IRS1, LEP, and ADIPOQ in SAT; LCAT, FOXA2,
KCNQ1, and GCKR in VAT; and PKD4, HNF4A,
XBP1, and PON1 in LT.
Interestingly, comparison between the DO and NDO
groups showed that several DMCs were shared among tis-
sues. DMCs located in CCDC185, MTHFD2, and SUMF1
overlapped between SAT and VAT; DMCs located in
FUCA1, C4orf33, PRAP1, SNX4, TMEM109, and ZNF597
overlapped between VATand LT; and DMCs inMIA2 over-
lapped between SAT and LT. Moreover, WB also showed
the DMCs in PSMD5, PAMR1, and SUMO3 found in SAT,
DMCs in SLC9A2 found in VAT; and DMCs in ALOX12
found in LT. DMCs in PSMD5, SLC9A2, and ALOX12
showed a significant correlation between WB and the other
tissues (Additional file 1: Figure S3). Additional file 1:
Tables S1-S4, show the complete list of DMCs.
We performed gene ontology enrichment analysis
using the genes with DMCs. The identified significant
gene ontology terms in SAT were mainly related to lipid
and carbohydrate metabolism and insulin response;
those in VAT were mainly related to cell death,
apoptosis, and cell cycle; and those in LT were mainly
related to wound healing, coagulation, and cell growth
(Additional file 1: Tables S5-S7). We found no signifi-
cantly enriched gene ontology terms in WB.
Effects of altered DNA methylation on gene expression
To understand the biological effects of altered methyla-
tion, we analyzed gene expression using HumanHT-12
v4 Expression BeadChips. Comparison between the DO
and NDO groups revealed subtle differential gene ex-
pression in all analyzed tissues (Additional file 1: Tables
S8-S11 and Figure S4). To determine whether the DNA
methylation differences between DO and NDO led to
functional effects in transcription, we investigated the
correlation of DNA methylation with gene expression
data, using a previously reported strategy [15]. Starburst
plots in Fig. 2 show the genes that displayed an inverse
correlation between altered DNA methylation and
Fig. 1 Differential methylation profiles from individuals with obesity and T2D. (a) Heat map shows the top 500 differentially methylated CpG sites.
Hierarchical clustering distinguishes NDO (blue bar) from DO samples (yellow bar). (b) Scatter plot of DNA methylation shows the average beta
values of NDO and DO patients. DMCs are highlighted in blue
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altered expression. Additional file 1: Tables S12-S15
show the complete list of these genes and the Additional
file 1: Table S16 shows the GO enrichment analysis.
Noteworthy, genes with the highest altered DNA methy-
lation (>|5%|) and altered expression included DST,
MGAT4C, LEP and ZNF3 in SAT; BRDT, C14orf105,
EDNRB, HMP19, PSG6 and SNX4 in VAT; and SYT7,
LTBR, CATSPER2, LPAL2, NCALD, ZDHHC11, LGTN,
OXT and PRSS21 in LT. Most of these genes have not
been previously related with T2D.
Discussion
Multiple studies have highlighted the importance of gen-
etic factors in the etiology of metabolic diseases; how-
ever, only a small fraction of susceptibility genes are
identified and few of them are reportedly shared among
these diseases. Emerging evidence supports the role of
epigenetic mechanisms as a crucial interface between
genetic and environmental influences [11]. Some studies
suggest that altered DNA methylation may be critical in
the development of obesity and T2D [12, 27, 28–30].
However, tissue specific mechanisms involved in obesity
and T2D are still unclear. To deepen our understanding
of the epigenomic mechanisms underlying T2D develop-
ment, here we analyzed the methylation and transcrip-
tion profiles in blood, liver, and subcutaneous and
visceral adipose tissue samples from individuals with
obesity, with and without T2D.
Comparison of DNA methylation profiles revealed a
high correlation among tissue of the same type
(Additional file 1: Figure S1), independent of T2D status,
showing an epigenetic footprint for each tissue type,
supporting the evidence that the developmental origin
and tissue environment are the primary determinants of
global DNA methylation patterns [31]. According whit
this conception, our comparison of DNA methylation
profiles among different tissues showed the strongest
correlation between subcutaneous and visceral adipose
tissues (Additional file 1: Figure S2), reflecting the high
functional similarity between them. A high correlation
between genome wide-DNA methylation of these tissues
was previously reported [32]. When we stratified by dia-
betic status, DNA methylation profiles revealed signifi-
cant differences in all analyzed tissues. Adjustment for
cell-type heterogeneity was performed only in blood
sample, since most of the broadly applied methods to
Fig. 2 Starburst plot for the comparison of DNA methylation and gene expression. Dashed black lines indicate p value of 0.05. Red points indicate genes
that are significantly down-regulated (DownReg) and hypermethylated (HyperMeth). Green points indicate genes that are significantly up-regulated
(UpReg) and hypomethylated (HypoMeth). DMCs are highlighted with black contour
Barajas-Olmos et al. BMC Medical Genetics  (2018) 19:28 Page 5 of 8
correct for cellular heterogeneity are based on methyla-
tion datasets from blood. A limitation is the lack of a re-
liable method for adjusting the variation in cellular
composition in fat and liver tissues. Another limitation
could be the relatively reduced number of sample which
could impact in the statistical power for identification of
altered methylation sites associated to T2D.
In agreement with previous findings, the most of the
altered DNA methylation sites showed hypomethylation
[16, 18–20]. Altered DNA methylation was mainly ob-
served in LT and in VAT, which enable clustering by
T2D status, as previously described [19, 20]. The lack of
available data for the accurate diagnosis and staging of
NAFLD/NASH involves a risk of stratification within the
groups, although in this study we do not identified CpGs
reported as altered in the progression of NAFLD/NASH
[33, 34]. SAT also showed differential methylation be-
tween the DO and NDO groups, although one of DO
cases was included among the controls, otherwise, methy-
lation analysis of WB did not cluster patients according to
T2D status. These findings, highlight the relevance of
insulin target tissues in T2D physiopathology and contri-
buting to the evidence of the importance of the epigenetic
role in the pathophysiology of these diseases [16].
As expected, several of the identified DMCs involved
genes previously reported with altered methylation pro-
files in T2D such as ADIPOQ, IRS1, and LEP in SAT and
KCNQ1 in VAT [35]. Remarkably, we found DMCs lo-
cated in the genes LCAT and FOXA2 in VAT, and PON1
and FGF21 in LT, which have been genetically associated
with metabolic traits, however, there are not enough
evidences of their altered methylation in these entities
[36–38]. Some of these genes have been involved in lipid
metabolism pathways, and although the DO showed
higher cholesterol and triglycerides serum levels, there
were not significant differences between both groups,
hence it is possible that their epigenetic regulation could
be involved in the interplay between the alteration of
lipid metabolism and the development of T2D [39, 40].
Although in this study the majority of DMCs were tis-
sue specific, some of them were shared among tissues,
perhaps representing common pathway in insulin-target
tissues and strengthening the previous suggestion that
adverse factors may similarly impact DNA methylation
in different tissues [12]. Interestingly, the altered methy-
lation of ALOX12 (LT), PSMD5 (SAT), and SLC9A2
(VAT) was significantly correlated between internal tis-
sues and blood, suggesting that particular DMCs could
be useful biomarkers. Further studies are needed to deli-
mitate the regions and CpG sites in blood that mirror
DNA methylation in other tissues. In this study 15/23
DO patients and 5/23 NDO patients were under metfor-
min treatment. The effect of metformin on DNA methy-
lation is still unclear and as far as we know, the unique
report on DNA methylation in diabetic patients treated
with metformin showed hypomethylation of SLC22A1,
SLC22A3 and SLC47A1 in liver, however, we found none
of these genes altered in our patients [41].
On the other hand, tissue-specific alterations in gene
expression have been reported in T2D [42–44], although
there are few reports involving the epigenomic regula-
tion on gene expression. Interestingly, all tissues of T2D
patients showed altered expression of genes involved in
the inflammation response—such as SOCS1 in WB;
CCL20 and SLAMF1 in SAT; ACP5, FOS, and JUN in
VAT; and PLA2G2A in LT, showing the relevance of the
systemic chronic inflammation in obesity and T2D [45].
We also found altered expression of genes involved in
adipogenesis (AMFR, ACP5, and FOSB) [46–48], a
process that is also widely reported in both diseases [49].
For better understanding of the role of epigenetic dys-
regulation in T2D, we integrated the methylation and
expression data. We found a direct impact of the altered
DNA methylation on expression of a subset of genes.
The pathways enriched with these genes included several
involved in T2D pathogenesis, such as adipogenesis,
regulation of apoptosis, mitochondrion organization,
oxygen transport, immune response and insulin resist-
ance. In addition, we found DNA methylation and
expression altered in genes having important roles in fat
storage and that had not previously been reported to
show epigenetic alteration in TD2—including SCT in
WB and SAT, OPRM1 in SAT, IRX3 in VAT, and NRG4
in LT. Our findings are in line with previous reports that
have pointed to epigenetic altered glycolytic and lipo-
genic pathways in T2D patients [19].
Conclusions
In summary, here we provide a catalog of genes affected
by altered methylation in liver, visceral and adipose tissues,
and peripheral blood samples from patients with obesity
and T2D. Our present results demonstrate tissue-specific
epigenetic alterations in individuals with obesity and T2D,
and highlight the roles of liver and adipose tissue in meta-
bolic disease development. Altered DNA methylation may
directly impact transcription, consequently altering several
pathways related to metabolic processes involved in T2D
etiopathogenesis. Here we present new evidence that al-
tered DNA methylation is a mechanism that affects these
processes in individuals with obesity developing T2D.
Overall, the available data suggest that altered methylation
of genes involved in cell metabolism could be a crucial
part of the mechanisms behind the comorbidity of meta-
bolic diseases. Further studies are needed to integrate the
available genetic and epigenetic data to improve our
understanding of the intriguing interplay between genetic
and environmental mechanisms in relation to the develop-
ment of complex traits, like T2D.
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